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Abstract
Background—Kidney pain is a common complication in patients with autosomal dominant 
polycystic kidney disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, 
a vasopressin V2 receptor antagonist, may have a positive effect on kidney pain in this patient 
group. Because pain is difficult to measure, the incidence of kidney pain leading to objective 
medical interventions was used in the present study to assess pain.
Study Design—Secondary analysis from a randomized controlled trial.
Setting & Participants—Patients with ADPKD with preserved kidney function.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Intervention—Tolvaptan or placebo.
Outcomes—Kidney pain events defined by objective medical interventions.
Measurements—Kidney pain events were recorded and independently adjudicated. Incidence of 
a first kidney pain event was assessed overall and categorized into 5 subgroups according to 
severity.
Results—Of 1,445 participating patients (48.4% women; mean age, 39 ± 7 [SD] years; mean 
estimated glomerular filtration rate, 81 ± 22 mL/min/1.73 m2; median total kidney volume, 1,692 
[IQR, 750–7,555] mL), 50.9% reported a history of kidney pain at baseline. History of urinary 
tract infections, kidney stones, or hematuria (all P < 0.001) and female sex (P < 0.001) were 
significantly associated with history of kidney pain. Tolvaptan use resulted in a significantly lower 
incidence of kidney pain events when compared to placebo: 10.1% versus 16.8% (P < 0.001), with 
a risk reduction of 36% (HR, 0.64; 95% CI, 0.48–0.86). The reduction in pain event incidence by 
tolvaptan was found in all groups irrespective of pain severity and was independent of 
predisposing factors (P for interaction > 0.05). The effect of tolvaptan was explained at least in 
part by a decrease in incidence of urinary tract infections, kidney stones, and hematuria when 
compared to placebo.
Limitations—Trial has specific inclusion criteria for total kidney volume and kidney function.
Conclusions—Tolvaptan decreased the incidence of kidney pain events independent of patient 
characteristics predisposing for kidney pain and possibly in part due to reductions in ADPKD-
related complications.
INDEX WORDS
Autosomal dominant polycystic kidney disease (ADPKD); pain; tolvaptan; vasopressin; acute 
kidney pain event; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal 
Dominant Polycystic Kidney Disease and Its Outcomes) 3:4; pain severity; analgesic
Pain is a common complication in patients with autosomal dominant polycystic kidney 
disease (ADPKD). It is a symptom that is often reported early in the disease course and that 
sometimes can be severe and difficult to manage and adversely affect a patient’s quality of 
life.1–3 Acute pain in patients with ADPKD can be caused by cyst hemorrhage, infection, 
and kidney stones, which are often accompanied by hematuria. When pain is present longer 
than 4 to 6 weeks, it is typically classified as chronic pain, which has a reported prevalence 
as high as 60%.4
The TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant 
Polycystic Kidney Disease and Its Outcomes) 3:4 trial demonstrated the renoprotective 
effects of tolvaptan treatment in a randomized controlled clinical trial setting.5 During 3 
years’ follow-up, tolvaptan, a vasopressin V2 receptor antagonist, reduced the annual rate of 
growth in total kidney volume (TKV) from 5.5% to 2.8% (P < 0.001) and the annual rate of 
estimated glomerular filtration rate (eGFR) decline from −3.70 to −2.72 mL/min/1.73 m2 (P 
< 0.001) compared to placebo.5 This trial also demonstrated a reduction in clinical 
progression as assessed by its key secondary composite end point through a reduction of 
ADPKD-related clinical events. This outcome was driven by 2 components of the 
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composite: time to decline in kidney function and time to clinically significant kidney pain 
events.5
In the present study, we explored this last finding more closely. We characterized what 
constituted a “clinically significant kidney pain event” by objectively examining the 
intensity of medical interventions used to define them. We also investigated the association 
of ADPKD clinical characteristics (such as history of kidney pain, infection, kidney stones, 
or hematuria at baseline) with the incidence of acute kidney pain events during the 3-year 
trial. Furthermore, we analyzed the effect of tolvaptan use on incidence of kidney pain 
events and explored whether new pain events were associated with baseline patient 
characteristics and the possible mechanisms by which tolvaptan reduced their incidence.
METHODS
Study Design and Patients
The present study was performed as a post hoc exploratory analysis of the TEMPO 3:4 trial, 
a prospective, blinded, randomized, placebo-controlled trial in patients with diagnosed 
ADPKD (ClinicalTrials.gov study number NCT00428948). Patients were enrolled at 129 
sites worldwide during January 2007 to January 2009. Inclusion criteria were age 18 to 50 
years with a diagnosis of ADPKD, TKV measured by magnetic resonance imaging ≥ 750 
mL, and creatinine clearance estimated by the Cockcroft-Gault formula ≥60 mL/min. 
Exclusion criteria included, among others, concomitant illnesses likely to confound end 
point assessments, such as diabetes mellitus, and prior kidney surgery. The institutional 
review board or ethics committee at each site approved the protocol. Written informed 
consent was obtained from all participants. Details of the study protocol6 and the primary 
study results5 have been published previously. This report has been prepared in accordance 
with the CONSORT (Consolidated Standards of Reporting Trials) 2010 Statement.7
Study Treatment
Patients were randomly assigned to receive tolvaptan or placebo (2:1). Tolvaptan dosing was 
started at 45 mg AM/15 mg PM (daily split dose) and increased weekly to 60/30 mg and 
90/30 mg if tolerated. Patients remained on the highest tolerated dose for 36 months.
Study Assessments and Definitions
Evaluations were performed at baseline, every 4 months during treatment, and twice for 2 to 
6 weeks after completion of treatment at 36 months and included interviews, examinations, 
vital sign measurements, and blood and trough spot morning urine samples. TKV was 
assessed using standardized kidney magnetic resonance imaging at baseline and months 12, 
24, and 36 or at early withdrawal. In addition, height-adjusted TKV was calculated as TKV 
in milliliters divided by height in meters. Serum creatinine level was reported to 2 decimal 
points and used to estimate GFR (applying the CKD-EPI [Chronic Kidney Disease 
Epidemiology Collaboration] equation).8
At baseline, a standardized interview was performed to gather information about 
demographic characteristics and medical history, including information for prior kidney 
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pain. Incidence of acute kidney pain during follow-up was a component of the composite 
secondary efficacy end point, which assessed kidney pain events requiring medical 
intervention and that required documentation of clinical signs and symptoms that pain was 
kidney related (ie, flank tenderness or evidence of cystic expansion or hemorrhage). The 
investigator’s clinical judgment was required to arbitrate whether the level of pain met the 
definition of end point, which required clinically significant kidney pain necessitating 
pharmacologic treatment or invasive intervention. Pain was a priori categorized according to 
the intensity of intervention into 5 groups: mild, prescription of acetaminophen; moderate, 
prescription of other non-narcotic analgesics; moderately severe, prescription of non-
narcotic analgesic and limitation in physical activity; severe, prescription of narcotic 
analgesics; most severe, need for hospitalization and/or invasive intervention. Events were 
assessed by an independent adjudication committee blinded for treatment allocation. Finally, 
the incidence of urinary tract infection, kidney stones, and hematuria was assessed as a 
composite score and separately. Of note, the initial TEMPO 3:4 trial publication provided 
data for these events only when reported as (serious) adverse events, whereas in the present 
study, all clinically significant pain-related adverse events are taken into account.
Study Outcomes
The primary end point in this study was the effect of tolvaptan use on incidence of acute 
kidney pain events compared to placebo. Second, we investigated: (1) the association of 
ADPKD clinical characteristics (such as history of kidney pain, infection, kidney stones, or 
hematuria at baseline) with the incidence of acute kidney pain events during the 3-year trial, 
(2) whether new acute kidney pain events were associated with baseline patient 
characteristics, and (3) the possible mechanisms by which tolvaptan reduced their incidence.
Statistical Analyses
Baseline characteristics were calculated for participants with and without a history of kidney 
pain separately. Normally distributed variables are expressed as mean ± standard deviation, 
whereas non–normally distributed variables are given as median (interquartile range [IQR]). 
Differences in baseline characteristics between patients with and without a history of kidney 
pain were calculated with χ2 test for categorical data, and for continuous data, with t test or 
Mann-Whitney U test in case of non–normally distributed data. To investigate whether 
baseline patient characteristics correlated with a history of kidney pain, univariate and 
multivariate logistic regression analyses were performed. The multivariate logistic analyses 
were subsequently adjusted for sex, age, height-adjusted TKV, and eGFR to investigate the 
impact of patient characteristics that predispose for kidney pain events that are not 
associated with disease severity. TKV, height-adjusted TKV, and albumin-creatinine ratio 
were log2-transformed to fulfill the requirement of normal distribution of the residuals for 
regression analysis.
In the placebo and tolvaptan groups, the overall incidence of a first acute kidney pain event 
during the 3-year trial was assessed in the intention-to-treat population, and the incidence of 
acute kidney pain events was subdivided in 5 categories named by pain severity and defined 
by the medical intervention used to treat the event. Cox proportional hazards regression 
analyses were performed to investigate whether baseline characteristics associated with the 
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first acute kidney pain event during the trial, with censoring of patients lost to follow-up or 
stopping study medication. First, unadjusted hazard ratios (HRs) with 95% confidence 
intervals were calculated. Second, we calculated multivariate-adjusted HRs, which were 
adjusted for sex, age, height-adjusted TKV, and eGFR to investigate the impact of patient 
characteristics that predispose for acute kidney pain events that are not associated with 
disease severity. The number needed to treat to prevent 1 acute kidney pain event was 
calculated based on the cumulative event proportions. In addition, we investigated the effect 
of tolvaptan on incidence of acute kidney pain events in the overall TEMPO 3:4 trial 
population and in subgroups according to baseline characteristics, and P for interaction by 
subgroup was calculated. Last, the effect of tolvaptan on renal complications known to cause 
pain was investigated.
Two sensitivity analyses were performed. First, the effect of tolvaptan on incidence of acute 
kidney pain events was investigated as time to first occurrence of each specific category of 
intervention/pain severity instead of as cumulative incidence. Second, the effect of tolvaptan 
was investigated including multiple acute kidney pain events per patient. All analyses were 
performed with SAS, version 9.2 statistical software (SAS Institute Inc), and 2-sided P < 
0.05 was considered to indicate statistical significance.
RESULTS
Baseline Characteristics
A total of 1,445 patients with ADPKD were enrolled in the TEMPO 3:4 trial (Fig 1). Mean 
age was 39 ± 7 years, and 48.4% were women (Table 1). By protocol, patients had preserved 
kidney function, with mean eGFR of 81 ± 22 mL/min/1.73 m2 and median TKV of 1,692 
(IQR, 750–7,555) mL. At baseline, 50.9% of participants reported having a history of kidney 
pain. Patient characteristics were stratified according to those with or without a history of 
kidney pain (Table 1). A history of urinary tract infection, kidney stones, or hematuria was 
associated with having a history of kidney pain. Other significant associations included 
female sex, smaller body size, and lower urine osmolality, although for the last 2 variables, 
the absolute difference between patients with and without a history of kidney pain was small 
and likely not clinically relevant. Each of these characteristics remained significant when 
adjusted for sex, age, height-adjusted TKV, and eGFR (Table S1, available as online 
supplementary material). No associations were found for history of kidney pain and eGFR, 
TKV, or height-adjusted TKV. Of the 1,445 participating patients, 484 were randomly 
assigned to placebo, and 961, to tolvaptan, of whom 49.4% and 51.6% had a history of 
kidney pain, respectively (P = 0.4). No significant differences in patient characteristics were 
observed between treatment groups when comparing participants with or without a history 
of pain.
Kidney Pain Events Over 3 Years in Placebo Group
In the placebo group, 16.7% of patients had an episode of kidney pain during the 3-year 
trial. A history of urinary tract infection, kidney stones, hematuria, or kidney pain and 
female sex tended to be associated with incident kidney pain events (Table 2). After 
adjusting for age, sex, height-adjusted TKV, and eGFR, these factors were significantly 
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associated with kidney pain events during the study, except for a history of urinary tract 
infection (Table 2). No association was found between baseline TKV, height-adjusted TKV, 
or eGFR with kidney pain events during follow-up; neither crude analysis nor analysis after 
multivariate adjustment for covariates.
Effect of Tolvaptan on Incidence of Kidney Pain Events
In contrast to the 16.7% incidence reported for patients in the placebo group, 10.1% of the 
tolvaptan group had clinically significant kidney pain during the 3-year trial. Identified risk 
factors for acute kidney pain events in the placebo group, for example, history of kidney 
stones, hematuria, or kidney pain and female sex, tended also to be associated with incident 
kidney pain events in the tolvaptan group (Table S2).
Tolvaptan use was associated with a significantly lower incidence of first kidney pain events 
when compared to placebo (P < 0.001), with a risk reduction of 36% (HR, 0.64; 95% 
confidence interval, 0.48–0.86; Table 3). The difference in cumulative incidence of patients 
having a kidney pain event between the tolvaptan and placebo groups increased over time 
(Fig 2). We analyzed the effects of tolvaptan on the incidence of kidney pain events among 
various subgroups based on specific baseline characteristics (Fig 3). No interactions were 
found between the effect of tolvaptan on kidney pain and patient characteristics of disease 
severity, characteristics predisposing for worse renal prognosis, or characteristics 
predisposing for kidney pain (P for interaction all nonsignificant). When pain was defined 
more strictly, similar efficacy of tolvaptan was noted (Table 3). The number needed to treat 
to prevent 1 pain event ranged from 35 patients when taking any pain event into account 
(prescription of acetaminophen or worse) to 384 patients when taking only the most severe 
pain category into account (hospitalization or invasive intervention; Table 3).
Last, we investigated whether the mechanism of tolvaptan in reducing kidney pain events 
could be elucidated. Patients with ADPKD having an acute kidney pain event had a similar 
TKV growth rate compared with patients with ADPKD who did not have such an event. 
This was the case for patients in the placebo group and those in the tolvaptan group (Table 
4). The significant reduction in number of participants having reported kidney pain was 
matched by similar reductions in the incidence of renal complications likely to cause such 
pain in ADPKD, such as urinary tract infections and kidney stones, and bouts of 
macroscopic hematuria that can be detected in patients having cyst ruptures and bleeds 
(infections, 11.1% vs 15.3% [P = 0.02]; kidney stones, 2.2% vs 3.5% [P < 0.001]; 
hematuria, 8.0% vs 14.3% [P < 0.001]; any of the 3 aforementioned, 18.9% vs 28.7% [P < 
0.001]). Irrespective of treatment arm, patients with kidney pain events had a higher 
incidence of these disease-related complications than those not having pain events.
Sensitivity Analyses
When pain events were analyzed by subgroup of pain severity instead of as cumulative 
incidence, risk reduction was observed for tolvaptan across all subgroups. Of note, relative 
risk reductions did not reach formal statistical significance in all subgroups, likely due to the 
small number of patients per pain category (Table S3). Sensitivity analysis focused on 
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multiple-event analyses yielded essentially the same result as the primary time-to-first-event 
analysis (Table S4).
DISCUSSION
Our study had a cross-sectional and a longitudinal part. In the cross-sectional analysis of 
baseline data of the TEMPO 3:4 trial, history of kidney pain was observed in 50.9% of 
participants. Acute kidney pain events in patients with ADPKD are often caused by urologic 
complications such as urinary tract infections, kidney stones, and cyst bleeding and rupture. 
The latter 2 are clinically diagnosed by bouts of macroscopic hemorrhage.1,2,4,9 In support 
of this, we found independent associations between history of kidney pain and history of 
urinary tract infection, kidney stones, and hematuria. Three prior studies have investigated 
the prevalence of pain in patients with ADPKD in a cross-sectional setting.10–12 The largest 
of these studies was performed by Miskulin et al10 using baseline data from 1,043 patients 
with ADPKD participating in the HALT–Polycystic Kidney Disease (PKD) studies. The 
authors described that pain is an early symptom in the course of ADPKD.10 The percentage 
of participants with a history of pain events in HALT-PKD was similar to the percentage of 
participants in the TEMPO 3:4 trial.5,10 Furthermore, they found that pain prevalence was 
inversely correlated with eGFR, but only in patients at lower eGFRs (<45 mL/min/1.73 
m2).10 In our study, we did not find such an association, which may be explained because 
TEMPO 3:4 enrolled patients with relatively preserved kidney function (estimated creatinine 
clearance > 60 mL/min).5 In the other 2 studies (involving 219 and 152 patients with 
ADPKD, respectively), pain was assessed in patients across a broad range of kidney 
function, including patients on dialysis therapy.11,12 These studies found that pain was 
positively correlated with the physical component score of health-related quality-of-life 
questionnaires, but they did not identify potential risk factors for kidney pain. We found that 
female sex was significantly associated with history of kidney pain, even when adjusted for 
height, age, and disease severity. To our knowledge, no other study has specifically reported 
this association. However, the study by Miskulin et al10 shows that a history of pain was also 
reported more by female compared with male patients with ADPKD. A history of back pain, 
for instance, was reported by 56.8% versus 45.1%, respectively.10 Medical and invasive 
treatments for pain were also more frequent in female patients. Whether this sex difference 
is specific for ADPKD is not clear. Several reviews have concluded, for instance, that in the 
general population, pain is more frequently reported by women than by men.13,14 It has been 
suggested that an interaction of biological (eg, sex hormones), psychological (eg, coping 
strategies), and sociocultural (eg, femininity) factors may contribute to this sex difference.13
In the longitudinal part of our study, 16.8% of patients in the placebo group reported acute 
kidney pain events during the 3-year trial. This is the first trial to prospectively investigate 
the incidence of such events in ADPKD. We found that history of kidney pain, kidney 
stones, and hematuria and female sex were associated with incident kidney pain. Therefore, 
our study shows in a cross-sectional and a longitudinal setting that these factors are 
associated with acute kidney pain.
In ADPKD, it is generally assumed that large kidney volumes play a role in causing pain. 
Interestingly, in this study, neither TKV nor height-adjusted TKV associated with acute 
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kidney pain at baseline (Table 1) or during the trial (Table 2). These results are supported by 
findings in the 539 patients in the study by Miskulin et al10 for whom magnetic resonance 
images were available. In these patients, no relationship was found between TKV and pain 
except in patients with very large kidneys. The authors proposed that cyst number, size, or 
location may be more important than TKV in causing pain. However, information for these 
variables was not available in their study and thus needs additional investigation. Others 
have suggested that the combined volume of the kidneys and liver is the major determinant 
of ADPKD-related symptoms, including pain.11,15 However, total liver volumes were not 
measured in TEMPO 3:4, so we can neither confirm nor reject this hypothesis.
During the trial, 10.1% of the tolvaptan group had events of clinically significant acute 
kidney pain compared to 16.8% of the placebo group, indicating a relative risk reduction by 
tolvaptan of 36% (Table 3). This pain incidence-lowering effect was found in all subgroups 
defined by intervention and was independent of baseline clinical characteristics shown to 
predispose for kidney pain. We attempted to determine a mechanism for the kidney pain-
lowering effect of tolvaptan. It was hypothesized that patients with a lower TKV growth rate 
would have a lower incidence of kidney pain events because tolvaptan reduced the rate of 
TKV growth by 49%.5 However, per-treatment-arm TKV growth rate was similar in patients 
having and not having a kidney pain event (Table 4). This finding, in combination with the 
lack of association between TKV and history of kidney pain at baseline (Table 1) and 
incident pain events during the trial (Table 2), suggests that the effect of tolvaptan on 
incidence of kidney pain events may not be primarily related to its effect on TKV growth 
rate.
Another mechanism may be related to a drug-related decrease in the incidence of renal 
complications that are known to be associated with acute kidney pain events (eg, a reduction 
in incidence of urinary tract infections, kidney stones, and cyst hemorrhage and ruptures 
[assessed as bouts of hematuria]). At baseline and during the trial, associations were found 
between these disease-related complications and history or incidence of kidney pain. 
Importantly, tolvaptan lowered the incidence of these complications compared to placebo: 
urinary tract infections, lowered by 27% (P = 0.02); kidney stones, lowered by 37% (P < 
0.001); and hematuria, lowered by 44% (P < 0.001; Table 4). In addition, a significantly 
higher incidence of these complications was observed in patients having versus not having a 
kidney pain event, irrespective of treatment arm. Tolvaptan-induced polyuria, which can be 
up to 4 to 6 L per day, might explain the lower incidence of these aforementioned renal 
complications because increased water intake is associated with lower recurrence of kidney 
stones and urinary tract infections in the general population.16 It may be that increasing 
water intake to such an extent without using tolvaptan could have a similar effect on acute 
kidney pain events. However, this has never been studied, and data in the literature suggest 
that it is questionable whether such high spontaneous water intake is feasible during 
prolonged periods.17 Our data indicate that the pain-lowering effect of tolvaptan might be 
mediated at least in part by a reduction in incidence of renal complications known to be 
associated with kidney pain. Of note, 58.8% of the tolvaptan group who had a kidney pain 
event did not report one of these complications. This suggests that other yet unidentified 
mechanisms may play a role. For instance, it might well be that tolvaptan reduces cyst fluid 
secretion and thereby fluid pressure within cysts, leading to fewer pain events. Another 
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possible additional mechanism may be the reflex increase in vasopressin concentration that 
is observed when the V2 receptor is blocked by tolvaptan.18,19 Vasopressin stimulates the 
secretion of β-endorphins by the hypothalamus, which could cause a central analgesic 
effect.20,21
The number needed to treat to prevent one acute kidney event is high to prescribe tolvaptan 
to patients with ADPKD with the sole aim of preventing such acute kidney pain events and 
should be weighed against the fact that in the TEMPO 3:4 trial, patients who were given 
tolvaptan had a greater number of adverse events related to aquaresis (ie, polydipsia, 
polyuria, and nocturia)5 and that tolvaptan has a potential hepatotoxic effect. The rates of all 
observed adverse events during the 3-year trial were discussed in more detail in the initial 
publication.5 Any potential benefit should of course be weighed against these disadvantages. 
In our opinion, the primary aim of prescribing tolvaptan for patients with ADPKD therefore 
remains its renoprotective efficacy. However, the present analyses indicate that when 
prescribed, there is an additional benefit that may be important, especially for patients with 
ADPKD with recurrent acute pain events. When considering whether to prescribe this drug, 
health care providers should carefully inform patients about potential risks and benefits.
There are limitations to our study worth addressing. First, this study was performed as a post 
hoc analysis of a randomized controlled trial. However, the outcome under study was 
prespecified per protocol. Second, the TEMPO 3:4 study had specific inclusion criteria for 
TKV and eGFR that were defined to enrich the patient population to be included for rapid 
disease progression. This may make extrapolation of our findings to the general ADPKD 
population difficult. However, neither the incidence of kidney pain events nor the effect of 
tolvaptan on kidney pain events was associated with baseline TKV or eGFR, suggesting that 
our results may be valid in the general ADPKD population. Third, the aquaretic response to 
tolvaptan causes polyuria. This may have caused unblinding in the study, which may have 
resulted in under- or overestimation of pain reporting. However, we assessed kidney pain 
events defined by objective criteria (ie, the need for medical intervention), and moreover, 
events were adjudicated by an independent committee that was blinded for treatment 
allocation. Therefore, we consider our data to be robust. Last, this study focuses on only 
acute kidney pain events and did not investigate the effect of tolvaptan on chronic pain in 
ADPKD, which is beyond the scope of the present study. The main strength of this study is 
that it was performed in a large population of patients with ADPKD in several countries 
across the world, making it seemingly the most comprehensive study available that 
investigates characteristics predisposing for kidney pain events among patients with ADPKD 
in a cross-sectional setting and the first study addressing this question in a longitudinal 
setting. Moreover, it describes the effect of tolvaptan as the first disease-modifying drug on 
kidney pain incidence, another important part of the ADPKD phenotype besides TKV 
growth and eGFR loss.
In conclusion, this study shows that a history of urinary tract infection, kidney stones, or 
hematuria and female sex were associated with a history of kidney pain at baseline, as well 
as with incident kidney pain events during the trial. No association was found between TKV 
and history of pain at baseline or with incident kidney pain events during the trial, indicating 
that kidney volume per se did not play a major role in causing pain. Tolvaptan use was 
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associated with a lower incidence of acute kidney pain events in all subgroups defined 
according to pain severity and independent of factors predisposing to pain incidence. The 
tolvaptan-induced reduction in incidence of renal complications, such as urinary tract 
infections, kidney stones, and hematuria, may at least in part explain the kidney pain-
lowering effect of this drug.
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Figure 1. 
Patient enrollment and outcomes.
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Figure 2. 
Cumulative incidence of patients having a first kidney pain event in tolvaptan- (blue solid 
line, n = 97) and placebo- (red dashed line, n = 81) treated patients from baseline to month 
36. Tolvaptan use was associated with a significantly lower incidence of first kidney pain 
events when compared to placebo, with a risk reduction of 36% (hazard ratio [HR], 0.64; 
95% confidence interval, 0.48–0.86; P < 0.001). Assessment of the assumption of 
proportional hazards indicated that the HR was constant over time (Figure S1).
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Figure 3. 
Effect of tolvaptan on first acute kidney pain events versus placebo during 3 years’ follow-
up in the overall study population and in subgroups according to baseline characteristics. 
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; HR, 
hazard ratio; hTKV, height-adjusted total kidney volume; N, number of participants; n, 
number of events; TKV, total kidney volume; UTI, urinary tract infection.
Casteleijn et al. Page 14
Am J Kidney Dis. Author manuscript; available in PMC 2017 July 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Casteleijn et al. Page 15
Table 1
Baseline Characteristics of TEMPO 3:4 Trial Participants Stratified According to History of Kidney Pain
History of Kidney Pain
Yes (n = 735) No (n = 710) P
Female sex 389 (52.9) 310 (43.7) <0.001
Age, y 38.8 ± 7.0 38.4 ± 7.2 0.2
Height, cm 172.9 ± 10.1 174.2 ± 10.1 0.01
Weight, kg 79.3 ± 18.4 79.0 ± 18.1 0.9
BMI, kg/m2 26.4 ± 5.3 25.9 ± 4.8 0.2
History of
 UTI 307 (41.9) 147 (20.7) <0.001
 Hematuria 318 (43.3) 185 (26.1) <0.001
 Kidney stones 196 (26.7) 100 (14.1) <0.001
 Liver cysts 450 (61.4) 412 (58.0) 0.2
Systolic BP, mm Hg 128.6 ± 13.3 128.5 ± 13.7 0.9
Diastolic BP, mm Hg 82.6 ± 9.5 82.4 ± 10.0 0.9
Use of BP-lowering drug 529 (72.0) 510 (71.8) 0.9
Presence of hypertension 609 (82.9) 583 (82.1) 0.7
eGFR, mL/min/1.73 m2 82.4 ± 21.8 80.8 ± 21.4 0.2
TKV, mL 1,694 ± 899 1,690 ± 912 0.7
hTKV, mL/m 976 ± 501 967 ± 508 0.5
Urine osmolality, mOsm/kg 493.4 ± 175.5 510.4 ± 181.8 0.04
ACR, mg/mmol 3.1 [1.2–8.1] 3.3 [1.1–8.8] 0.2
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median 
[interquartile range].
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; hTKV, 
height-adjusted total kidney volume; TEMPO, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease 
and Its Outcomes; TKV, total kidney volume; UTI, urinary tract infection.
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Table 2
Associations of Baseline Characteristics With First Kidney Pain Events During 3 Years’ Follow-up in the 484 
Placebo-Treated Patients in TEMPO 3:4 Trial
Crude Adjusted for Age, Sex, hTKV, eGFR
HR (95% CI) P HR (95% CI) P
Female sex 2.01 (1.27–3.20) 0.003 2.15 (1.33–3.45) 0.002
Age, per 5 y older 0.97 (0.83–1.13) 0.7 0.99 (0.83–1.18) 0.9
Height, per 5 cm greater 0.85 (0.75–0.96) 0.01 0.92 (0.78–1.09) 0.3
Weight, per 5 kg greater 0.95 (0.89–1.02) 0.1 0.98 (0.91–1.06) 0.6
BMI, per 1 kg/m2 greater 1.00 (0.95–1.04) 0.8 1.00 (0.95–1.05) 0.9
History of
 Kidney pain 2.24 (1.40–3.58) <0.001 2.15 (1.33–3.48) 0.002
 UTI 2.00 (1.28–3.12) 0.002 1.54 (0.94–2.51) 0.08
 Hematuria 1.55 (0.99–2.43) 0.1 1.75 (1.10–2.79) 0.01
 Kidney stones 1.63 (1.01–2.64) 0.04 1.84 (1.13–3.00) 0.01
Systolic BP, per 5 mm Hg greater 1.00 (0.92–1.09) 0.9 1.03 (0.95–1.12) 0.5
Diastolic BP, per 5 mm Hg greater 1.08 (0.95–1.21) 0.2 1.12 (0.99–1.26) 0.1
Use of BP-lowering drug 0.88 (0.54–1.44) 0.6 0.93 (0.55–1.58) 0.8
Presence of hypertension 1.20 (0.63–2.27) 0.6 1.36 (0.69–2.69) 0.4
eGFR, per 5 mL/min/1.73 m2 greater 1.00 (0.96–1.06) 0.8 1.00 (0.94–1.06) 0.9
Log TKV, per doubling of TKV in mL 0.96 (0.67–1.37) 0.8 0.14 (0.76–1.73) 0.3
Log hTKV, per doubling of hTKV in mL/m 1.02 (0.71–1.45) 0.9 1.17 (0.77–1.75) 0.5
Urine osmolality, per 50 mOsm/kg greater 0.98 (0.92–1.04) 0.4 0.98 (0.92–1.04) 0.5
Log ACR, per doubling of ACR in mg/mmol 1.09 (0.95–1.25) 0.2 1.08 (0.93–1.26) 0.3
Note: In multivariate analyses, risks were adjusted for age, sex, hTKV, and eGFR. In case the association between eGFR and first acute kidney pain 
event was investigated, the variable eGFR was not incorporated twice in the model.
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular 
filtration rate; HR, hazard ratio; hTKV, height-adjusted total kidney volume; TEMPO, Tolvaptan Efficacy and Safety in Management of Autosomal 
Dominant Polycystic Kidney Disease and Its Outcomes; TKV, total kidney volume; UTI, urinary tract infection.
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Table 3
Cumulative Incidence of Patients Having a Kidney Pain Event During 3 Years’ Follow-up According to 
Severity of Pain as Scored by Intensity of Intervention
Pain Severity Pain Events/100 person-y F/U HR (95% CI) NNT P
Mild or worse (overall)
 Tolvaptan 5.09 0.64 (0.48–0.86) 35 <0.001
 Placebo 8.09
Moderate or worse
 Tolvaptan 4.05 0.62 (0.45–0.86) 39 0.01
 Placebo 6.74
Moderately severe or worse
 Tolvaptan 2.94 0.67 (0.45–1.00) 64 0.05
 Placebo 4.55
Severe or worse
 Tolvaptan 2.31 0.74 (0.46–1.18) 94 0.2
 Placebo 3.40
Most severe
 Tolvaptan 0.21 0.22 (0.04–1.14) 384 0.07
 Placebo 0.38
Abbreviations and Definitions; CI, confidence interval; F/U, follow-up; HR, hazard ratio; mild, prescription of acetaminophen; moderate, 
prescription of non-narcotic analgesics; moderately severe, limitation in physical activity; most severe, need for hospitalization and/or invasive 
intervention; NNT, number needed to treat; severe, prescription of narcotic analgesics.
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